重组复合干扰素治疗普通干扰素治疗复发和无应答的慢性丙型肝炎32例

A clinical trial of consensus interferon for treatment of 32 patients with chronic hepatitis C and non-response and relapse for IFN-a2b

目的探讨复合干扰素(consensus Interferon,CIFN)干复津治疗复发及无应答慢性丙型肝炎的疗效。方法对32例普通干扰素治疗无应答或治疗后复发的慢性丙型肝炎患者,用干复津15μg治疗,每周3次,皮下注射,疗程24周。观察治疗过程中、结束时及停药半年后随访的临床症状、体征、ALT、HCV-RNA持续应答率及不良反应情况。结果31例患者完成治疗,治疗24周时完全应答率和随访6月时持续应答率分别为67.74%和41.93%。普通干扰素治疗的复发组和无应答组经干复津治疗结束后HCV-RNA持续阴转率分别为67.8%和19.35%(P<0.05),复发组较无应答组具有较好的疗效。两组均未发现严重不良反应。结论复合干扰素15μg单独用于治疗复发或无应答的慢性丙型肝炎有较好的疗效。

Objective To investigate the therapeutic effects of consensus interferon （CITF）in treatment of patients with chronic hepatitis C and non- response or relapse for interferon -a2b. Methods Thirty - two patients with chronic hepatitis C, who had been non - response and relapse for interferon - a2b therapy, were treated by CITF. The CITF （ 15μg, 3 vices every week） was applied for 24 weeks in all of 32 patients. The clinical symptom, sign, response rate of ALT, HCV - RNA and adverse effect were observed on different time point of during treatment, end - point of treatment and follow - up period of 6 months after treatment. Results The completely response rate on 24 weeks of CITF therapy and the continue response rate of follow-up period on 6 months after treatment were 67.74 % and 41.93 %, respectively. The continue response rate of serum HCV- RNA abolition in relapsed patients for interferon- cc2h therapy and in non- response patients for interferon- a2h were 67.8 % and 19.35 %, respectively （P 〈 0.05） ）. Conclusion The simple CITF therapy for non - response and relapsed cases for interferon - a2b therapy possesses reasonable effect in chronic hepatitis C.